Improving treatment for ovarian cancer by delivering gene-silencing therapy
Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system
This study is exploring a new way to deliver a special treatment that targets a protein linked to ovarian cancer, aiming to improve therapy options for patients by using tiny gold particles to help the treatment work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11003353 on NIH RePORTER |
What this research studies
This research focuses on developing a new delivery system for small interfering RNA (siRNA) that targets a protein called MICU1, which is involved in ovarian cancer metabolism and treatment resistance. By using advanced techniques, including in vitro cell cultures and in vivo animal models, the researchers aim to create a gold nanoparticle-based liposomal formulation that can effectively deliver siRNA to silence MICU1. This innovative approach seeks to overcome current limitations in siRNA delivery, potentially leading to more effective therapies for ovarian cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer who may benefit from novel gene-silencing therapies.
Not a fit: Patients with other types of cancer or those not diagnosed with ovarian cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for ovarian cancer by normalizing the metabolism that contributes to therapy resistance.
How similar studies have performed: While gene silencing approaches have shown promise in other contexts, this specific delivery system for ovarian cancer treatment is relatively novel and has not been extensively tested.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Mukherjee, Priyabrata — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Mukherjee, Priyabrata
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.